Magnetic Drug Targeting - A new approach in locoregional tumortherapy with chemotherapeutic agents. Experimental animal studies

被引：58

作者：

Alexiou C. ^{[1
,5
]}

Jurgons R. ^{[1
]}

Schmid R. ^{[1
]}

Erhardt W. ^{[2
]}

Parak F. ^{[3
]}

Bergemann C. ^{[4
]}

Iro H. ^{[1
]}

机构：

[1] Klinik und Poliklinik für Hals-Nasen-Ohren-Kranke, Universität Erlangen-Nürnberg

[2] Institut für Experimentelle Onkologie und Therapieforschung, Klinikum Rechts der Isar, Technische Universität München

[3] Physik-Department E 17, Technische Universität München

[4] Chemicell GmbH, Berlin

[5] Klinik und Poliklinik für Hals-Nasen-Ohren-Kranke, Universität Erlangen-Nürnberg, 91054 Erlangen

来源：

HNO | 2005年 / 53卷 / 7期

关键词：

Ferrofluids; Intra-arterial chemotherapy; Magnetic Drug Targeting; Magnetic nanoparticles; Nanotechnology;

D O I：

10.1007/s00106-004-1146-5

中图分类号：

学科分类号：

摘要：

Background. Advanced squamous cell carcinomas of the head and neck region were often treated with combined radio-chemotherapy. Radiotherapy allows a focused treatment of the tumor, and healthy tissue can be protected from radiation. Chemotherapy, however, is mostly given systemically and the unwanted negative side effects also develop in many other organs. Aim of the study. Locoregional application of chemotherapeutic agents with Magnetic Drug Targeting on an animal experimental study. Methods and results. Magnetic Drug Targeting is a new approach to the locoregional treatment of tumors. Ferrofluids (colloidal dispersion of magnetic nanoparticles) were reversibly bound to chemotherapeutic agents and injected intra-arterially, while focused with an external magnetic field to a certain body compartment (i.e. the tumor). With only 20% or 50% percent of the regular systemic chemotherapeutic dose, we achieved an up to 26 times higher concentration in the tumor region with this application compared to the usual systemic administration. Conclusion. Magnetic Drug Targeting offers an unique opportunity to treat tumors locoregionally with chemotherapeutic agents. © Springer Medizin Verlag 2004.

引用

页码：618 / 622

页数：4

共 14 条

[1]

Alexiou C., Arnold W., Klein R., Et al., Locoregional cancer treatment with magnetic drug targeting, Cancer Res, 60, pp. 6641-6648, (2000)

[2]

Alexiou C., Arnold W., Hulin P., Et al., Magnetic mitoxantrone nanoparticle detection by histology, x-ray and MRI after magnetic drug targeting, J Magnetism Magn Mater, 225, pp. 187-193, (2001)

[3]

Alexiou C., Schmidt A., Klein R., Hulin P., Bergemann C., Arnold W., Magnetic drug targeting: Biodistribution and dependency on magnetic field strength, J Magnetism Magn Mater, 252, pp. 363-366, (2002)

[4]

Daniilidis J., Constantinidis J., Fountzilas G., Combined radiochemotherapy in locally advanced nasopharyngeal carcinoma, HNO, 49, pp. 732-738, (2001)

[5]

Eckardt A., Kelber A., Pytlik C., Palliativ intra-arterial (ia) chemotherapy with carboplatin (CBDCA) and 5-FU in unresectable advanced (stage III-IV) head and neck cancer using implantable port systems, Eur J Surg Oncol, 21, pp. 486-489, (1995)

[6]

Hilger I., Hiergeist R., Hergt R., Winnefeld K., Schubert H., Kaiser W.A., Thermal ablation of tumors using magnetic nanoparticles: An in vivo feasibility study, Invest Radiol, 37, pp. 580-586, (2002)

[7]

Lubbe A.S., Bergemann C., Riess H., Et al., Clinical experiences with magnetic drug targeting: A phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors, Cancer Res, 56, pp. 4686-4693, (1996)

[8]

Robbins K.T., Vicario D., Seagren S., Et al., A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer, Am J Surg, 168, pp. 419-442, (1994)

[9]

Sagowski C., Kehrl W., Hegewisch-Becker S., Wenzel S., Jaehne M., Panse J., Nierhaus A., Tumor oxygenation in combined whole body hyperthermia and polychemotherapy. Studies exemplified by recurrent carcinoma of the mouth cavity, HNO, 48, pp. 949-954, (2000)

[10]

Scheel Jv., Kastenbauer E., Intraarterielle Cisplatin-Therapie beim adenoid-zystischen Karzinom, HNO, 29, pp. 308-311, (1981)

← 1 2 →